<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167553</url>
  </required_header>
  <id_info>
    <org_study_id>HM-GCG-102</org_study_id>
    <nct_id>NCT04167553</nct_id>
  </id_info>
  <brief_title>Study for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities</brief_title>
  <official_title>A Phase 1, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The planned period of each cohort is 22 weeks including subject screening, treatments for 12&#xD;
      weeks, and follow up period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Actual">December 9, 2020</completion_date>
  <primary_completion_date type="Actual">December 9, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events (AEs):</measure>
    <time_frame>after multiple subcutaneous (SC) doses for 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Obese With Comorbidities</condition>
  <condition>Overweight With Comorbidities</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>HM15136</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM15136</intervention_name>
    <description>In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.</description>
    <arm_group_label>HM15136</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female subjects&#xD;
&#xD;
          2. Age ≥ 18 to ≤ 65 years at Screening visit&#xD;
&#xD;
          3. Body Mass Index ( BMI ≥ 30 kg/m 2 or 27 kg/m 2 with presence of comorbidities&#xD;
             (Subjects in Part 1 and Subjects with Pre diabete s mellitus (DM) in Part 2:&#xD;
             dyslipidemia and or hypertension except for Type 2 (T2) DM, T2DM subjects in Part 2:&#xD;
             dyslipidemia and/or hypertension with T2DM) with/without medication treatment and have&#xD;
             had stable weight for 3 months (weight changes less than 5%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or&#xD;
             any other gastrointestinal surgery that may induce malabsorption, history of bowel&#xD;
             resection &gt; 20 cm, any malabsorption disorder, severe gastroparesis, any GI procedure&#xD;
             for weight loss (including LAPBAND®), as well as clinically significant&#xD;
             gastrointestinal disorders (e.g. peptic ulcers, severe GERD ) at Screening.&#xD;
&#xD;
          2. Use of antacids, anticoagulants, or drugs that directly modify gastrointestinal (GI)&#xD;
             motility, including antacid s anticholinergics, anticonvulsants, serotonin type 3&#xD;
             (5HT3) antagonists, dopamine antagonists, opiates; anticoagulation within 2 weeks of&#xD;
             screening (But, it is not limited to the above listed drugs.)&#xD;
&#xD;
          3. Uncontrolled hypertension, defined as systolic blood pressure &gt; 160 mmHg and/or&#xD;
             diastolic blood pressure ≥ 100 mmHg at screening independent of subjects being on&#xD;
             antihypertensive medication or no t). But, if the results are out of the reference&#xD;
             range at the screening visit, they can be tested again on another day. Subjects with&#xD;
             uncontrolled hypertension may be rescreened after 3 months, following initiation or&#xD;
             adjustment of antihyp ertensive therapy.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prosciento</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

